Press Releases Novavax, Inc.

Equities

NVAX

US6700024010

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-16 pm EDT			After hours 07:00:35 pm
10.08 ^USD	-1.51%		10.25	+1.69%

Mar. 10	Novavax, Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-10-2026 03:40 PM
Mar. 03	Novavax, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 02:30 PM

Press Releases

Feb. 26	Novavax to Participate in Upcoming Investor Conferences	PR
Feb. 26	Novavax: Q4 Earnings Snapshot	AQ
Feb. 26	Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights	PR
Feb. 19	Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026	PR
Jan. 20	Novavax Announces Entering into a License Agreement with Pfizer	PR
Jan. 07	Novavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference	PR
Nov. 12	Novavax to Participate in Jefferies London Healthcare Conference	PR
Nov. 06	Novavax : Q3 Reports & Financials (nvax q3 25 earnings presentation)	PU
Nov. 06	Novavax: Q3 Earnings Snapshot	AQ
Nov. 06	Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights	PR
Nov. 04	Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment	PR
25-10-30	Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025	PR
25-10-22	Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy	PR
25-10-07	Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment	PR
25-09-30	Novavax Announces Progress on Sanofi Agreement	PR
25-09-19	Novavax : Sanofi and Novavax Statement on Nuvaxovid™ COVID-19 vaccine for ACIP	PU
25-09-04	Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment	PR
25-09-03	Novavax : Statement on Publicly Available COVID-19 Vaccine Data	PU
25-09-03	Novavax to Participate in the Cantor Global Healthcare Conference	PR
25-08-27	Novavax's Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S.	PR
25-08-27	FDA approves updated COVID-19 shots but limits access for some kids and adults	AQ
25-08-21	Novavax Announces Convertible Debt Refinancing	PR
25-08-06	Novavax: Q2 Earnings Snapshot	AQ
25-08-06	Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights	PR
25-07-30	Novavax to Report Second Quarter 2025 Financial Results on August 6, 2025	PR